scholarly journals Prognostic Role of the Pretreatment C-Reactive Protein/Albumin Ratio in Solid Cancers: A Meta-Analysis

2017 ◽  
Vol 7 (1) ◽  
Author(s):  
Nan Li ◽  
Guang-Wei Tian ◽  
Ying Wang ◽  
Hui Zhang ◽  
Zi-hui Wang ◽  
...  
Keyword(s):  
Meta Analysis ◽  
C Reactive Protein ◽  
Prognostic Role ◽  
Albumin Ratio ◽  
Reactive Protein

scholarly journals The Prognostic Role of Glasgow Prognostic Score and C-reactive Protein to Albumin Ratio for Sarcoma: A System Review and Meta-Analysis

2020 ◽  
Vol 2020 ◽  
pp. 1-14 ◽  
Author(s):  
Erhu Fang ◽  
Xiaolin Wang ◽  
Jiexiong Feng ◽  
Xiang Zhao
Keyword(s):  
Fixed Effects ◽  
Meta Analysis ◽  
Prognostic Score ◽  
Glasgow Prognostic Score ◽  
Fixed Effects Model ◽  
C Reactive Protein ◽  
Prognostic Role ◽  
Albumin Ratio ◽  
Reactive Protein

Backgrounds. Both pretreatment serum CRP (C-reactive protein) level and ALB (albumin) level have been found to be predictive of survival for multiple malignancies including sarcoma. Since both of the GPS (Glasgow prognostic score) and CAR (C-reactive protein to albumin ratio) are based on the combination of CRP and ALB, we conducted a meta-analysis to evaluate the prognostic role of these two parameters for sarcoma patients. Methods. A detailed literature search was conducted in MEDLINE, Embase, and Cochrane Library for relevant research publications written in English. Patients’ clinical characteristics, outcomes of overall survival (OS), disease-specific survival (DSS), and disease-free survival (DFS) were extracted. Pooled hazard ratios (HRs) and corresponding 95% confidence intervals (CIs) were combined to evaluate the prognostic role of GPS or CAR. Results. Twelve articles containing 2695 patients were identified as eligible studies. The results showed that an elevated GPS was significantly correlated with poor OS (HR=2.42; 95% CI: 1.98-2.94; p<0.001; fixed-effects model), DSS (HR=2.28; 95% CI: 1.75-2.97; p<0.001; fixed-effects model), and DFS (HR=2.05; 95% CI: 1.62-2.60; p<0.001; fixed-effects model). A higher CAR also was shown to be significantly correlated with poor OS (HR=2.23; 95% CI: 1.70-2.92; p<0.001; fixed-effects model) and DFS (HR=1.81; 95% CI: 1.7-2.58; p=0.001; fixed-effects model). Conclusion. An elevated GPS is predictive of poor survival in patients with sarcomas and is promising to be used as a factor for risk stratification. A higher CAR value is also predictive of poor survival; however, the optimal CAR cut-off value is still to be determined.

scholarly journals Prognostic Role of the C-Reactive Protein/Albumin Ratio in Patients With Gynecological Cancers: A Meta-Analysis

2021 ◽  
Vol 11 ◽  
Author(s):  
Yingji Fang ◽  
Tingting Zheng ◽  
Chengling Zhang
Keyword(s):  
Meta Analysis ◽  
Disease Free Survival ◽  
Cochrane Library ◽  
Gynecological Cancers ◽  
C Reactive Protein ◽  
Prognostic Role ◽  
Albumin Ratio ◽  
Reactive Protein ◽  
Gynecology And Obstetrics

BackgroundMany studies have investigated the prognostic role of the C-reactive protein/albumin ratio (CRP/Alb ratio) in patients with gynecological cancers; however, there is lack of consensus owing to conflicting results across studies. We performed a meta-analysis to determine the prognostic role of the CRP/Alb ratio in gynecological cancers.MethodsWe searched the PubMed, Embase, the Web of Science, Cochrane Library, China National Knowledge Infrastructure, and Wanfang electronic databases since inception to April 2021. Combined hazard ratios (HRs) and 95% confidence intervals (CIs) were used to estimate the prognostic effect of the CRP/Alb ratio in gynecological cancers. Pooled odds ratios (ORs) and 95% CIs were used to investigate the association between the CRP/Alb ratio and clinicopathological features.ResultsThe meta-analysis included seven studies with 1,847 patients. The pooled results showed that a high pretreatment CRP/Alb ratio was associated with poor overall survival (HR, 1.84; 95% CI, 1.41–2.40; p &lt; 0.001) and progression-/disease-free survival (HR, 2.58; 95% CI, 1.42–4.68; p = 0.002). Additionally, a high CRP/Alb ratio was significantly associated with stages III–IV disease (the International Federation of Gynecology and Obstetrics classification) (OR, 2.98; 95% CI, 1.45–6.14; p = 0.003). However, we observed a non-significant correlation between the CRP/Alb ratio and lymph node metastasis, tumor size, and histopathological grade.ConclusionsThe CRP/Alb ratio is a convenient and accurate predictor of survival outcomes in gynecological cancers. A high CRP/Alb ratio also predicts tumor progression.

scholarly journals Prognostic role of the pretreatment C-reactive protein/albumin ratio in gastric cancer

Medicine ◽  
2020 ◽  
Vol 99 (10) ◽  
pp. e19362
Author(s):  
Xuanxuan Yang ◽  
Xing Song ◽  
Luo Zhang ◽  
Changping Wu
Keyword(s):  
Gastric Cancer ◽  
C Reactive Protein ◽  
Prognostic Role ◽  
Albumin Ratio ◽  
Reactive Protein

scholarly journals Prognostic role of pre-treatment C-reactive protein/albumin ratio in esophageal cancer: a meta-analysis

BMC Cancer ◽  
2019 ◽  
Vol 19 (1) ◽  
Author(s):  
Zhenhua Liu ◽  
Hongtai Shi ◽  
Longyun Chen
Keyword(s):  
Esophageal Cancer ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Pooled Analysis ◽  
Cochrane Library ◽  
C Reactive Protein ◽  
Albumin Ratio ◽  
Reactive Protein ◽  
Pre Treatment

Abstract Background In recent years, the role of pre-treatment C-reactive protein/albumin ratio (CAR) in prognosis of esophageal cancer (EC) has been investigated by several studies. This meta-analysis aimed to provide a more accurate and objective assessment of the prognostic value of pre-treatment CAR in EC. Methods Studies assessing the role of pre-treatment CAR in prognosis of EC were searched from PubMed, Embase and the Cochrane Library (last update by April 16, 2019). The hazard ratios (HRs) of CAR and the corresponding 95% CIs for overall survival (OS) or cancer-specific survival (CSS) in EC were extracted for pooled analysis. Results A total of eight observational studies including 2255 patients were collected. The pooled analysis showed that high CAR was related to worse OS in EC (pooled HR = 1.81; 95% CI = 1.40–2.35; P < 0.001). Subgroup analyses showed that the negative correlation between the CAR and OS was consistently demonstrated in subgroups stratified by country, pathological type, and cut-off value (P < 0.05). However, there was no relation between CAR and OS in subgroup of patients receiving neoadjuvant chemotherapy at a proportion of 100% (HR = 1.15, 95% CI = 0.56–2.69; P = 0.715). In addition, high CAR was also related to worse CSS in EC (pooled HR = 2.61; 95% CI = 1.67–4.06; P < 0.001). Conclusions High pre-treatment CAR was an adverse prognostic factor for EC patients. More large-sample clinical trials are still needed to verify the prognostic value of pre-treatment CAR in EC.

scholarly journals Prognostic role of C-reactive protein in prostate cancer: a systematic review and meta-analysis

2014 ◽  
Vol 16 (3) ◽  
pp. 467 ◽  
Author(s):  
Qing Xu ◽  
Yi-Jing Chen ◽  
Zhu-Qing Liu ◽  
Li Chu ◽  
Jue-Min Fang ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Meta Analysis ◽  
C Reactive Protein ◽  
Prognostic Role ◽  
Reactive Protein

scholarly journals Prognostic Role of C-Reactive Protein In Urological Cancers: A Meta-Analysis

2015 ◽  
Vol 5 (1) ◽  
Author(s):  
Liang Zhou ◽  
Xiang Cai ◽  
Qiang Liu ◽  
Zhong-Yu Jian ◽  
Hong Li ◽  
...  
Keyword(s):  
Meta Analysis ◽  
C Reactive Protein ◽  
Prognostic Role ◽  
Reactive Protein ◽  
Urological Cancers

scholarly journals Prognostic Role of C-reactive Protein in Gastric Cancer: A Meta-analysis

2013 ◽  
Vol 14 (10) ◽  
pp. 5735-5740 ◽  
Author(s):  
Qing Yu ◽  
Xiong-Fei Yu ◽  
Shou-De Zhang ◽  
Hao-Hao Wang ◽  
Hai-Yong Wang ◽  
...  
Keyword(s):  
Gastric Cancer ◽  
Meta Analysis ◽  
C Reactive Protein ◽  
Prognostic Role ◽  
Reactive Protein
Sign in / Sign up

Export Citation Format

Share Document